{"id":"5-azacitidine","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Myelosuppression"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1489","moleculeType":"Small molecule","molecularWeight":"244.21"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"5-Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to a decrease in DNA methylation and an increase in gene expression.","oneSentence":"Inhibits DNA methyltransferase","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:50.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT06514261","phase":"PHASE1","title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-18","conditions":"Acute Myeloid Leukemia","enrollment":45},{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT00658814","phase":"PHASE2","title":"Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12-01","conditions":"Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":133},{"nctId":"NCT06317649","phase":"PHASE2","title":"Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-27","conditions":"Acute Myeloid Leukemia","enrollment":147},{"nctId":"NCT05554393","phase":"PHASE2","title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-13","conditions":"Acute Myeloid Leukemia","enrollment":153},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT07388563","phase":"PHASE1","title":"Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":20},{"nctId":"NCT01861314","phase":"PHASE1","title":"Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-03","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia","enrollment":15},{"nctId":"NCT01627041","phase":"PHASE2","title":"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-16","conditions":"Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":178},{"nctId":"NCT00392353","phase":"PHASE1, PHASE2","title":"Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-11-22","conditions":"Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":135},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT07071155","phase":"EARLY_PHASE1","title":"Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-19","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms","enrollment":18},{"nctId":"NCT03041688","phase":"PHASE1","title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-08","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":58},{"nctId":"NCT05554406","phase":"PHASE2","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-25","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":335},{"nctId":"NCT00336063","phase":"PHASE1","title":"Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-03-03","conditions":"Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Nasopharyngeal Undifferentiated Carcinoma","enrollment":18},{"nctId":"NCT01522976","phase":"PHASE2","title":"Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-03-01","conditions":"Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2","enrollment":282},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT03874052","phase":"PHASE1","title":"Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Jennifer Saultz","startDate":"2019-08-16","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia","enrollment":51},{"nctId":"NCT04799275","phase":"PHASE2, PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":422},{"nctId":"NCT07486726","phase":"PHASE1, PHASE2","title":"Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-15","conditions":"Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT06379360","phase":"PHASE2","title":"Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-11-01","conditions":"Acute Myeloid Leukemia","enrollment":77},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05636514","phase":"PHASE1","title":"Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS","status":"RECRUITING","sponsor":"Clinical Hub for Interventional Research (CHOIR)","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT04256317","phase":"PHASE2, PHASE3","title":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2020-05-21","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm","enrollment":316},{"nctId":"NCT04588922","phase":"PHASE1, PHASE2","title":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","status":"RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-05-10","conditions":"Hematologic Malignancies","enrollment":160},{"nctId":"NCT04282187","phase":"PHASE2","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-03-24","conditions":"Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome","enrollment":25},{"nctId":"NCT07387354","phase":"PHASE1, PHASE2","title":"Pacritinib With Aza for Upfront Myelodysplastic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2026-05","conditions":"Myelodysplastic Syndromes, MDS, Myelodysplastic Syndrome, Unclassifiable","enrollment":25},{"nctId":"NCT07283900","phase":"PHASE2","title":"Ascorbate in Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Prajwal Dhakal","startDate":"2026-03-11","conditions":"Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT05379166","phase":"PHASE2","title":"Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Uma Borate","startDate":"2022-06-23","conditions":"Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT06763341","phase":"PHASE1","title":"A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-07-30","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT06523556","phase":"PHASE1, PHASE2","title":"Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Uma Borate","startDate":"2024-08-02","conditions":"Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":52},{"nctId":"NCT05226455","phase":"PHASE1, PHASE2","title":"Venetoclax in Patients With MDS or AML in Relapse After AHSCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2022-11-23","conditions":"MDS, AML","enrollment":55},{"nctId":"NCT03471260","phase":"PHASE1, PHASE2","title":"Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-19","conditions":"Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome","enrollment":96},{"nctId":"NCT03862157","phase":"PHASE1, PHASE2","title":"Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-02-27","conditions":"Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Not Otherwise Specified","enrollment":40},{"nctId":"NCT05834244","phase":"PHASE1","title":"A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-26","conditions":"Acute Myeloid Leukemia","enrollment":32},{"nctId":"NCT03404193","phase":"PHASE2","title":"Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-01-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":235},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT04128501","phase":"PHASE2","title":"Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-05","conditions":"Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT07060001","phase":"PHASE2","title":"Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)","enrollment":112},{"nctId":"NCT03683433","phase":"PHASE2","title":"Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-09-18","conditions":"Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia","enrollment":50},{"nctId":"NCT04734990","phase":"PHASE1, PHASE2","title":"Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-07","conditions":"Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2","enrollment":44},{"nctId":"NCT05768711","phase":"PHASE2","title":"Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2023-10-04","conditions":"Chronic Myeloid Leukemia","enrollment":44},{"nctId":"NCT07451912","phase":"PHASE1, PHASE2","title":"Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-15","conditions":"Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML","enrollment":29},{"nctId":"NCT06498973","phase":"PHASE1","title":"Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-01-28","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":43},{"nctId":"NCT02530463","phase":"PHASE2","title":"Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-08","conditions":"Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome","enrollment":99},{"nctId":"NCT03969446","phase":"PHASE1","title":"Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-05-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT07304011","phase":"PHASE2","title":"Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-12-17","conditions":"Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT03844815","phase":"PHASE1","title":"Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-18","conditions":"Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT07148947","phase":"PHASE2","title":"Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-03-02","conditions":"Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm","enrollment":27},{"nctId":"NCT06177067","phase":"PHASE1","title":"Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-04-19","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":24},{"nctId":"NCT07283094","phase":"PHASE1","title":"FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-02-03","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT04263181","phase":"","title":"AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-29","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":80},{"nctId":"NCT03358719","phase":"PHASE1","title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-03-27","conditions":"Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia","enrollment":8},{"nctId":"NCT07433023","phase":"PHASE2","title":"tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy","status":"NOT_YET_RECRUITING","sponsor":"Shirley Ryan AbilityLab","startDate":"2026-03-01","conditions":"Cerebral Palsy","enrollment":80},{"nctId":"NCT07434492","phase":"PHASE2","title":"Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy","status":"NOT_YET_RECRUITING","sponsor":"Shirley Ryan AbilityLab","startDate":"2026-03-01","conditions":"Cerebral Palsy","enrollment":60},{"nctId":"NCT03974217","phase":"PHASE1","title":"Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-08-01","conditions":"Leukemia","enrollment":13},{"nctId":"NCT03850418","phase":"PHASE2","title":"Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2019-07-01","conditions":"Myeloid Malignancy","enrollment":43},{"nctId":"NCT06445907","phase":"PHASE1","title":"Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-12","conditions":"Acute Myeloid Leukemia","enrollment":32},{"nctId":"NCT04061421","phase":"PHASE1, PHASE2","title":"Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)","status":"RECRUITING","sponsor":"Michael Savona","startDate":"2021-11-24","conditions":"MDS/MPN","enrollment":94},{"nctId":"NCT07425808","phase":"PHASE2, PHASE3","title":"FLT3-ITD Targeted Therapy in Fit AML Patients","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2026-12-01","conditions":"AML (Acute Myeloid Leukemia)","enrollment":230},{"nctId":"NCT04964505","phase":"PHASE1","title":"Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Brian Jonas","startDate":"2021-07-02","conditions":"Acute Myeloid Leukemia","enrollment":16},{"nctId":"NCT07177079","phase":"PHASE1","title":"High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)","status":"NOT_YET_RECRUITING","sponsor":"Kittika Poonsombudlert","startDate":"2026-05-31","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT07389239","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06-23","conditions":"Ovarian Cancer, Advanced Malignant Solid Tumor","enrollment":24},{"nctId":"NCT03383575","phase":"PHASE2","title":"Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-01-17","conditions":"Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia","enrollment":63},{"nctId":"NCT02816021","phase":"PHASE2","title":"Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-02-14","conditions":"Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma","enrollment":24},{"nctId":"NCT07407660","phase":"PHASE3","title":"Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-02-01","conditions":"Acute Myeloid Leukemia","enrollment":250},{"nctId":"NCT04160052","phase":"PHASE1, PHASE2","title":"Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-01","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome","enrollment":51},{"nctId":"NCT07404332","phase":"PHASE1","title":"5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mohammed Milhem","startDate":"2026-02-28","conditions":"Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor","enrollment":35},{"nctId":"NCT07018752","phase":"PHASE1, PHASE2","title":"A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2025-08-20","conditions":"Peripheral T Cells Lymphoma (PTCL)","enrollment":49},{"nctId":"NCT01515527","phase":"PHASE2","title":"Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-07","conditions":"Leukemia","enrollment":160},{"nctId":"NCT04803201","phase":"PHASE2","title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-08","conditions":"Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma","enrollment":170},{"nctId":"NCT07172204","phase":"PHASE2","title":"Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-16","conditions":"Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60","enrollment":25},{"nctId":"NCT07259707","phase":"PHASE2","title":"Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-01-25","conditions":"Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication Positive, Intermediate Risk Acute Myeloid Leukemia","enrollment":25},{"nctId":"NCT06091267","phase":"PHASE1, PHASE2","title":"PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Beijing Research Institute","startDate":"2023-10-16","conditions":"Myelodysplastic Syndromes","enrollment":72},{"nctId":"NCT04447027","phase":"PHASE1","title":"Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma","enrollment":26},{"nctId":"NCT06397027","phase":"PHASE1","title":"A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-12-27","conditions":"Refractory Acute Leukemia, Pediatric Relapsed","enrollment":22},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT05455294","phase":"PHASE1","title":"Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2022-07-18","conditions":"Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis","enrollment":16},{"nctId":"NCT07372352","phase":"PHASE2","title":"Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-15","conditions":"Peripheral T Cells Lymphoma (PTCL)","enrollment":26},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT03264404","phase":"PHASE2","title":"Azacitidine and Pembrolizumab in Pancreatic Cancer","status":"COMPLETED","sponsor":"Susan E. Bates","startDate":"2017-10-01","conditions":"Pancreas Cancer","enrollment":36},{"nctId":"NCT06997094","phase":"PHASE1","title":"Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-23","conditions":"Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT04139434","phase":"PHASE1","title":"Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML","status":"COMPLETED","sponsor":"Newave Pharmaceutical Inc","startDate":"2020-07-06","conditions":"AML/MDS, CMML, Relapse","enrollment":32},{"nctId":"NCT05442216","phase":"PHASE2","title":"Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents","status":"RECRUITING","sponsor":"Joshua Zeidner","startDate":"2024-05-01","conditions":"Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT02961101","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies","status":"RECRUITING","sponsor":"Han weidong","startDate":"2016-05","conditions":"Malignancies Multiple","enrollment":250},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT04747236","phase":"PHASE2","title":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2021-02-19","conditions":"PTCL","enrollment":50},{"nctId":"NCT05038592","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-04","conditions":"Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2","enrollment":64},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT04891068","phase":"PHASE2","title":"BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2022-01-10","conditions":"Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":40},{"nctId":"NCT04062266","phase":"PHASE2","title":"AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-13","conditions":"Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder","enrollment":50},{"nctId":"NCT04266301","phase":"PHASE3","title":"Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":530},{"nctId":"NCT05183035","phase":"PHASE3","title":"Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"PedAL BCU, LLC","startDate":"2022-10-01","conditions":"Acute Myeloid Leukemia","enrollment":98},{"nctId":"NCT03875287","phase":"PHASE1","title":"Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-04-17","conditions":"Solid Tumor","enrollment":35},{"nctId":"NCT03661307","phase":"PHASE1, PHASE2","title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-31","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":274,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VIDAZA","Azacitidine","5-azacytidine","5-aza","Vidaza"],"phase":"phase_2","status":"active","brandName":"5-Azacitidine","genericName":"5-Azacitidine","companyName":"Shirley Ryan AbilityLab","companyId":"shirley-ryan-abilitylab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits DNA methyltransferase Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}